Vantive, formerly the Baxter Kidney Care segment, has officially launched as an independent company dedicated to vital organ therapies. With a 70-year legacy in kidney care innovation, Vantive ...

Interim CEO Brent Shafer highlighted the completion of the Vantive sale as a significant milestone in Baxter's transformation strategy and noted the company's focus on innovation and profitable ...

--(BUSINESS WIRE)--Baxter International Inc. (NYSE ... the company’s targeted future sales growth excluding sales to Vantive under the Kidney Care manufacturing and supply agreement (MSA ...

Super helpful as we look at the company post Vantive. For my first question. The past several years for Baxter have been characterized by exogenous events like Hurricane Helene, elevated ...

Brent Shafer; Chair and Interim Chief Executive Officer; Baxter International Inc Heather Knight; Executive Vice President, Chief Operating Officer; Baxter International Inc Joel Grade ...

Barclays analyst Matt Miksic maintained a Buy rating on Baxter International (BAX – Research Report) on March 7 and set a price target of ...

Nicholas Baxter’s usual moral balance involves the scales of justice at work in the district attorney’s office each week, but what happens when that delicate equilibrium tips over into his ...

Barclays reinstated coverage of Baxter (BAX) with an Overweight rating and $39 price target The firm updated its sales projections to reflect the company’s continuing operations, which exclude ...

Transformation Update and Senior Leadership Changes Baxter completed the sale of its Kidney Care business, now known as Vantive, to Carlyle for approximately $3.4 billion of net, after-tax ...

Slamdance is nearing the final day of its 2025 edition, a historic one for the festival founded in 1995 as a scrappy alternative to Sundance. The cinematic showcase has made a new home for itself ...